GlassScriptPhysician profile
Jeffrey Ryan Pua
NPI 1689831778
$24,552.78
in general payments reported to CMS, 2019-2025
51 companies · $408 in 2025
The $408 reported for 2025 was more than what a typical Obesity Medicine (Internal Medicine) provider received nationally (typical 2025 total: $202).
See the full distribution for Obesity Medicine (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,576 · 2020: $4,780 · 2021: $5,541 · 2022: $4,733 · 2023: $2,990 · 2024: $1,524 · 2025: $408.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,877 · Education: $45.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,876.89 |
| Education | $45.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $5,412.72 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $2,696.47 | 2021-2025 | |
| Lilly USA, LLC | $2,591.21 | 2019-2024 | Jardiance, Mounjaro, Trulicity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,863.15 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Amarin Pharma, INC. | $1,346.95 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $1,160.74 | 2019-2024 | Farxiga, Airsupra |
| Bayer Healthcare Pharmaceuticals INC. | $1,030.46 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $844.27 | 2019-2022 | |
| Corcept Therapeutics | $733.92 | 2019-2024 | Korlym |
| Merck Sharp & Dohme LLC | $585.98 | 2019-2023 | Steglatro, Belsomra |
| Takeda Pharmaceuticals U.S.A., INC. | $536.70 | 2019-2023 | Trintellix |
| Dexcom, INC. | $452.41 | 2022-2023 | Dexcom G6 Transmitter |
| Currax Pharmaceuticals LLC | $447.86 | 2019-2024 | Contrave, Onzetra Xsail, Nexletol |
| Teva Pharmaceuticals USA, INC. | $402.23 | 2019-2021 | |
| Endo Pharmaceuticals INC. | $366.74 | 2019-2023 | Nascobal |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Pua listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.